Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

BACKGROUND: CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2. We present interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM vaccine with two different adjuvant formula...

Descripción completa

Detalles Bibliográficos
Autores principales: Goepfert, Paul A, Fu, Bo, Chabanon, Anne-Laure, Bonaparte, Matthew I, Davis, Matthew G, Essink, Brandon J, Frank, Ian, Haney, Owen, Janosczyk, Helene, Keefer, Michael C, Koutsoukos, Marguerite, Kimmel, Murray A, Masotti, Roger, Savarino, Stephen J, Schuerman, Lode, Schwartz, Howard, Sher, Lawrence D, Smith, Jon, Tavares-Da-Silva, Fernanda, Gurunathan, Sanjay, DiazGranados, Carlos A, de Bruyn, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055206/
https://www.ncbi.nlm.nih.gov/pubmed/33887209
http://dx.doi.org/10.1016/S1473-3099(21)00147-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055206/
https://www.ncbi.nlm.nih.gov/pubmed/33887209
http://dx.doi.org/10.1016/S1473-3099(21)00147-X

Ejemplares similares